
DXCM
USDDexCom Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$61.090
고가
$62.390
저가
$58.880
거래량
8.96M
기업 기본 정보
시가총액
23.9B
산업
의료 기기
국가
United States
거래 통계
평균 거래량
5.54M
거래소
NMS
통화
USD
52주 범위
AI 분석 리포트
마지막 업데이트: 2025년 11월 4일DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?
Market Pulse Check
- Current Price: $60.43 (as of 2025-11-03 close)
- Recent Swing: +3.8% rebound after 61% decline since August highs
- Key Technicals: MACD bearish crossover vs. surging 19x average volume
Price Action Breakdown
- August-Sept Stability: Traded $75-$82 range
- Sept 19 Crash: -11% drop on 3x average volume
- October Freefall: 35% decline accelerated by legal news
- November Lifeline: +3.8% gain on massive 17.8M shares traded
News Impact Matrix
| Sentiment | Count | Key Developments |
|---|---|---|
| Negative | 9 | 6 law firm investigations filed |
| Analyst Mixed | 12 | 8 lowered PTs (range $75-$99) |
| Positive | 1 | New board member appointment |
AI Forecast Snapshot
| Timeframe | Prediction | Notes |
|---|---|---|
| 1-day | -0.8% | Potential pullback after surge |
| 2-day | +1.6% | Technical rebound potential |
| 3-day | +1.9% | Resistance near $62 area |
Strategic Considerations
For Active Traders:
- Watch $61.15 breakout level (Nov 3 high)
- Consider partial profits at $62.90 TP
- Hard stop below $58.50 support
Long-term Investors:
- Monitor lawsuit developments closely
- Debt concerns (94% D/E ratio) require scrutiny
- Potential accumulation zone if $58 holds
Bottom Line
DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.
This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.
관련 뉴스
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...
UBS Maintains Buy on DexCom, Lowers Price Target to $95
UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...
Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93
Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.
AI 예측Beta
AI 추천
업데이트 시간: 2025년 11월 4일 오후 09:09
60.6% 신뢰도
리스크 & 트레이딩
진입점
$58.80
익절
$62.91
손절
$52.39
핵심 요소
관련 주식
VLRS
Controladora Vuela Compania de Aviacion S.A.B. de C.V. American Depositary Shares each representing ten (10) Ordinary Participation Certificates
IP
International Paper
AMAT
Applied Materials
TIXT
TELUS International (Cda) Inc. Subordinate Voting Shares
BWA
BorgWarner
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기